Events / News

MGC Diagnostics Names Frederic Gavage Managing Director of Medisoft S.A.



St. Paul, MN, (November 2, 2015) MGC Diagnostics (NASDAQ: MGCD), a global medical technology company, announced today that Frederic Gavage has been named Managing Director of MediSoft S.A., a wholly‐owned subsidiary of MGC Diagnostics, effective immediately. Mr. Gavage will be responsible for the general management of MediSoft and will play a key role in the implementation of the Company’s corporate strategy.

For the past 10 years, Mr. Gavage provided Management Consulting and Audit Services. Recently, Mr. Gavage provided Management Consulting Services on behalf of Deloitte Belgium to develop and implement enhanced operating systems at Medisoft. He holds advanced degrees in Auditing and Business Economics.

Todd Austin, Chief Executive Officer of MGC Diagnostics, commented, “We are pleased to have Frederic Gavage join our team as Managing Director of MediSoft. Fred has a strong skill set gained from his experiences with Deloitte Consulting, and being actively involved in the day‐to‐day operation of Medisoft during the past 14 months. His working knowledge of Medisoft will be very beneficial as we begin a new fiscal year and build upon the financial improvements that Medisoft made during fiscal year 2015."

About MGC Diagnostics

MGC Diagnostics Corporation (NasdaqCM: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its subsidiaries Medical Graphics Corporation and MediSoft SA, develops, manufactures and markets non‐invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company’s products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university‐based medical centers, medical clinics, physicians’ offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit

Cautionary Statement Regarding Forward‐Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward‐looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words “believes,” “expects,” “anticipates,” “intends” or similar expressions. For these forward‐looking statements, the Company claims the protection of the safe harbor for forward‐looking statements contained in federal securities laws. These forward‐looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward‐looking statements. For a list of these factors, see the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements”, in the Company’s Form 10‐K for the year ended October 31, 2014, and any updates in subsequent filings on Form 10‐Q or Form 8‐K under the Securities Exchange Act of 1934.


Wesley W. Winnekins
MGC Diagnostics Corporation
Chief Financial Officer
+1 651.484.4874

Joe Dorame, Robert Blum, Joe Diaz
Lytham Partners, LLC
+1 602.889.9700